Shorting a few shares, no big deal. We are up against a system that is willing to sacrifice 100,000's of lives if not millions just to insure that their drug is the one brought to market. If Leronlimab had saved only 5 percent that is still 250,000 people, but nobody is counting anymore. We still have Remdesivir.